Showing results (141-150 of 715) with videos related to
Sort By:
Pageof 72
Psycho-Oncology|September 19, 2024
Associations Between a Social Determinant of Health Summary Measure and Self-Reported Physical and Mental Health Among Cancer SurvivorsMeng-Han Tsai, Steven S Coughlin, Minjee Lee, et al.Current Hematologic Malignancy Reports|June 11, 2011
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemiaMichael S Mathisen, Susan O'Brien, Deborah Thomas, et al.Clinical Lymphoma, Myeloma & Leukemia|March 6, 2014
Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapyAlfonso Quintás-Cardama, Sangbum Choi, Hagop Kantarjian, et al.Journal of Cancer Research and Clinical Oncology|March 10, 2017
Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemiaVerena S Hoffmann, Joerg Hasford, Michael Deininger, et al.Cancers|August 29, 2024
Global Trial Representation and Availability of Tyrosine Kinase Inhibitors for Treatment of Chronic Myeloid LeukemiaMycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, et al.Cancer|February 28, 2007
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patternsHagop M Kantarjian, Jorge Cortes, Francçois Guilhot, et al.Clinical Lymphoma, Myeloma & Leukemia|September 25, 2013
Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remissionAlfonso Quintás-Cardama, Srdana Grgurevic, Uri Rozovski, et al.Cancer|March 15, 2006
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapyC Cameron Yin, Jorge Cortes, Bedia Barkoh, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2009
A multinational study of health state preference values associated with chronic myelogenous leukemiaShelagh M Szabo, Adrian R Levy, Catherine Davis, et al.Leukemia Research|July 16, 2003
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemiaEfrosyni Apostolidou, Jorge Cortes, Apostolia Tsimberidou, et al.Pageof 72